Gilead posts ZUMA-24 results for axi-cel in LBCL; denikitug trial still active, not recruiting
Gilead's Kite unit posted results for a completed Phase 2 study of axicabtagene ciloleucel with steroid prophylaxis, while a separate denikitug trial in GI cancers remains active, not recruiting.
This week's update covers two Gilead-related oncology trials, one with newly posted results and one unchanged in status.
- NCT05459571, sponsored by Kite, a Gilead Company, is a completed Phase 2 study titled "A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting," known as ZUMA-24. The record lists a status of completed, with primary and study completion dated 2025-11-24, and results first posted 2026-11-12.1 Enrollment reached 35 participants, with participants receiving lymphodepleting chemotherapy followed by prophylactic corticosteroid treatment with 10 mg dexamethasone before and after axicabtagene ciloleucel infusion.1 Participants completing at least 18 months of follow-up were transitioned to a separate long-term follow-up study to complete the remainder of 15-year follow-up assessments.1
- NCT07546812, sponsored by Gilead Sciences, is a Phase 2 trial of denikitug (GS-1811) given alone or with nivolumab, or with ramucirumab and paclitaxel, in HER2-negative gastric, GEJ, and esophageal adenocarcinomas. The record lists the status as active not recruiting, with an actual start date of 2026-08-07 and estimated primary completion in 2030-01.2 Enrollment is estimated at 120 participants,2 and the study's primary objective is to assess the effect of DEN as monotherapy or in combination with nivolumab or ramucirumab and paclitaxel on objective response rate assessed by the investigator per RECIST Version 1.1.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.